Genetic screening identifies the atypical tetraspanin TM4SF1 as a strong mediator of metastatic reactivation of breast cancer. Intriguingly, TM4SF1 couples the collagen receptor tyrosine kinase DDR1 to the cortical adaptor syntenin 2 and, hence, to PKCa. The latter kinase phosphorylates and activates JAK2, leading to the activation of STAT3. This non-canonical mechanism of signaling induces the expression of SOX2 and NANOG; sustains the manifestation of cancer stem cell traits; and drives metastatic reactivation in the lung, bone, and brain. Bioinformatic analyses and pathological studies corroborate the clinical relevance of these findings. We conclude that non-canonical DDR1 signaling enables breast cancer cells to exploit the ubiquitous interstitial matrix component collagen I to undergo metastatic reactivation in multiple target organs.
INTRODUCTION
Experiments in mouse models and analysis of clinical data suggest that disseminated breast cancer cells enter into a protracted state of proliferative dormancy before undergoing reactivation and causing metastatic relapse (Aguirre-Ghiso, 2007) . In spite of their clinical relevance, tumor dormancy and reactivation remain poorly understood. Notably, it is unclear if they are mediated by core signaling pathways and transcriptional circuits that operate in multiple target organs.
The metastasis-initiating cells enter into dormancy and eventually undergo reactivation in response to niche signals that are part of the extracellular matrix, embedded in it, or exposed on the surface of adjacent stromal or epithelial cells (Giancotti, 2013) . Dormancy-inducing signals include bone morphogenetic protein 4 (BMP4), which is produced by lung-resident cells and suppresses the self-renewal capability of breast cancer cells that have infiltrated this organ. Tumor cells eventually avert BMP4 inhibition by producing the transforming growth factor b (TGF-b) ligand inhibitor Coco, which reinstates their proliferative capacity (Gao et al., 2012) . Similarly, BMP7 and TGF-b2 have been implicated in dormancy of prostate and squamous cell carcinoma, respectively (Bragado et al., 2013; Kobayashi et al., 2011) . Stimulatory and inhibitory signals can be physically segregated along the abluminal surface of blood vessels, as mature endothelial cells produce thrombospondin, which induces dormancy, whereas angiogenic endothelial cells produce periostin, tenascin C, versican, and TGF-b, which promote metastatic outgrowth (Ghajar et al., 2013) . As most of the reactivation signals have been studied in models of breast cancer metastasis to lung, it remains unclear if they can function across organ sites.
We recently developed mouse genetic screens that enable the isolation of genetic entities involved in breast cancer reactivation (Gao et al., 2014) . Here, we show that the top hit from one such screen, the tetraspanin TM4SF1, promotes reactivation in multiple organs and elucidate the underlying mechanism. (legend continued on next page)
RESULTS

TM4SF1 Mediates Breast Cancer Reactivation in the Lung
Tail-vein injection of dormant 4TO7 cells transduced with cDNA libraries from metastatic 4T1 cells enabled the isolation of lung metastatic derivatives ( Figure S1A ) (Gao et al., 2012) . cDNAs encoding the divergent tetraspanin TM4SF1 were recovered from 44 metastases that had arisen in eight mice. 4TO7 cells re-transduced with TM4SF1 colonized the lung efficiently, corroborating the strong pro-metastatic activity of this hit (Gao et al., 2014) . Conversely, silencing of TM4SF1 suppressed the capacity of 4T1, MDA-MB231, and ErbB2-transformed (Guo et al., 2006) breast cancer cells to colonize the lung, pointing to a requirement for TM4SF1 in this process .
Consistent with a role for TM4SF1 in metastatic reactivation, its depletion did not reduce the number of viable tumor cells seeding the lung but suppressed their capacity to resume proliferation (Figures 1B, S1F, and S1G). To directly implicate TM4SF1 in this process, we used a doxycycline-regulated promoter to express it in 4TO7 cells, either immediately or 2 weeks after tail vein injection (Figures 1C and S1H) . Whereas immediate expression of TM4SF1 induced metastatic outgrowth around day 7 post-injection, expression beginning at day 14 caused it around day 21 ( Figures 1D, 1E , and S1I). Thus, a delay in induction of TM4SF1 causes a similar delay in metastatic outgrowth, directly implicating TM4SF1 in metastatic reactivation.
TM4SF1 is an evolutionarily divergent tetraspanin upregulated in lung, colon, breast, and ovarian carcinomas (Hellstrom et al., 1986; Marken et al., 1992 Marken et al., , 1994 . High levels of TM4SF1 mRNA in primary tumors correlated with reduced relapse-free survival in ER À but not ER + patients ( Figure 1F ; n = 3,455), presumably because estrogen receptor (ER) signaling suppresses TM4SF1 expression in the latter (Al Saleh et al., 2011; Gao et al., 2014) . Staining of clinically annotated tissue micro arrays (TMAs) (Table  S1 ) indicated that high levels of expression of TM4SF1 in primary tumors correlate with reduced metastasis-free survival, suggesting that TM4SF1 promotes metastatic relapse in patients (Figures 1G and 1H) . Finally, hypothesizing that TM4SF1 had a signaling function, we used its transcriptional program as a predictor of its involvement in metastasis. Consistently, we found that an 8-gene signature induced by TM4SF1 strongly predicts early relapse in unfractionated patients from a large dataset (Figures 1I, 1J, and S1J; n = 855) . Multivariate analysis showed that this discrete signature is an independent predictor of poor prognosis (Table S2) . These results are consistent with a role for TM4SF1 in metastatic reactivation of human breast cancer.
TM4SF1 Promotes Cancer Stem Cell Traits
Silencing of TM4SF1 inhibited the capacity of 4T1 and ErbB2 cells to form tumor organoids in 3D Matrigel but did not inhibit tumor cell survival, proliferation, or migration under standard culture conditions (Figures 2A, 2B , and S2A-S2D). Moreover, inactivation of TM4SF1 reduced tumor incidence and tumor growth and prolonged latency after injection of limiting numbers of ErbB2 cells in the mammary fat pad of NSG mice (Figures 2C and 2D, left) . Statistical analysis confirmed that silencing of TM4SF1 reduces the frequency of tumor-initiating cells (Table  S3) . Similar results were obtained in secondary transplantation experiments, in spite of the increase in tumor initiating cells and hence the outgrowth of larger tumors ( Figures 2C and 2D right, note different scales; Table S3 ). Finally, although silencing of TM4SF1 did not affect the expression of the stem cell markers CD24, CD29, Sca1, and CD49f ( Figure S2E ), it almost completely suppressed the transcription of the pluripotency factors Sox2, Oct4, and Nanog ( Figure 2E ). These results indicate that TM4SF1 promotes the manifestation of cancer stem cell traits.
TM4SF1 Responds to Collagen I and Causes Metastatic Reactivation in Multiple Organs
Considering the role of specialized ECM niches in metastatic reactivation, we asked if TM4SF1 mediates outgrowth in response to a specific matrix component. Intriguingly, treatment with soluble collagen I, but not collagen IV, fibronectin, or laminin 1, greatly enhanced the capacity of ErbB2 cells to form primary and secondary tumor spheres ( Figure 2F ). Silencing of TM4SF1 reversed the stimulatory effect of collagen I in both cases (Figures 2G and S2F) . Similar results were obtained with the MDA-MB231 cells ( Figure S2G ). Collagen fibers, especially if extensively crosslinked by lysil-oxidase (LOX), promote integrin-mediated activation of Rho kinase (ROCK), facilitating FAK/ Src signaling (Levental et al., 2009 Figure S1 and Tables S1 and S2. Figure S2 and Table S3 .
of ROCK with Y-27632 nor of LOX with BAPN or a function blocking antibody suppressed tumor sphere formation in response to collagen I, suggesting that this process does not require integrinmediated mechanotransduction ( Figure 2H ). Because Matrigel contains minimal amounts of collagen I, we asked if it supported the outgrowth of tumor organoids by enabling the retention of tumor-produced collagen I. Consistently, we found that several breast cancer cells produce and deposit collagen I in the pericellular matrix to levels similar or higher as compared to those of mouse embryo fibroblasts ( Figure S2H ). Moreover, we detected a clear rim of collagen I at the tumor-Matrigel interface in organoids grown in 3D Matrigel ( Figure S2I ). Finally, antibodies to human collagen I inhibited the ability of MDA-MB231 cells to form tumor spheres in the absence of exogenous collagen I, suggesting that the basal outgrowth of these spheres depends on autocrine collagen I signaling ( Figure S2J ). These observations suggest that TM4SF1 specifically enhances self-renewal in response to collagen I.
Given the ubiquitous presence of collagen I in the interstitial matrix, we examined if TM4SF1 mediates colonization not only of the lung but also of additional organs. Depletion of TM4SF1 suppressed the capacity of ErbB2 and 4T1 cells to produce bone and brain metastases and severely reduced the ability of the bone-tropic MDA-MB231 derivatives, BoM-1833, to colonize the bone (Figures 3A-3E and S3). Quantification of the solitary tumor cells and metastases present in bone and brain sections 3 weeks after injection indicated that silencing of TM4SF1 selectively blocks the ability of solitary tumor cells to outgrow into metastases ( Figure 3F ). These findings indicate that TM4SF1 is required for metastatic reactivation in multiple organs.
TM4SF1 Promotes Clustering of DDR1
TM4SF1 has diverged significantly from canonical tetraspanins during evolution, suggesting a distinctive function (Wright et al., 2000) . Analysis of Pathway Commons pointed to a potential interaction of TM4SF1 with the collagen receptor tyrosine kinase DDR1 and the cortical scaffold syntenin 2 ( Figure 4A ). Consistently, Myc-TM4SF1 combined efficiently with Flag-DDR1, but not Flag-DDR2, in 293T cells lysed in radioimmunoprecipitation assay (RIPA) buffer and endogenous TM4SF1 associated to a lower extent with endogenous DDR1 in ErbB2 cells solubilized under the same conditions . In contrast to canonical tetraspanins, recombinant TM4SF1 did not combine with endogenous av or b1 integrins, which include all known collagen-binding heterodimers, in MCF-7 cells ( Figure S4D ). DDR1 and DDR2 are slowly activated by fibrillar and nonfibrillar collagens and exert partially redundant functions during development (Leitinger, 2011) . Because DDR1 is amplified in a fraction of breast, pancreatic and ovarian cancer cell lines (Marcotte et al., 2012) and DDR1 protein is heavily phosphorylated on tyrosine in squamous lung carcinoma (Rikova et al., 2007) , we first focused on the DDR1-TM4SF1 interaction. Mutational analysis indicated that the extracellular portion of DDR1 is necessary for interaction with TM4SF1, whereas the transmembrane and cytoplasmic domains of the receptor are dispensable ( Figure 4C ). Considering the structure of DDR1 and TM4SF1 (Carafoli et al., 2012; Marken et al., 1994; Xu et al., 2014) , we presume that the discoidin-like domain or the $50 amino acid-long, highly flexible membrane-proximal segment of the ectodomain of DDR1 interacts with the extracellular loop connecting the third and fourth transmembrane segments of TM4SF1.
Following engagement by fibrillar collagens, DDR1 dimers undergo multimerization leading to the formation of receptor clusters (Mihai et al., 2009; Noordeen et al., 2006) . To study the role of TM4SF1 in this process, we used immunofluorescent staining because a large fraction of DDR1 and TM4SF1 becomes insoluble in multiple detergents-including RIPA buffer-in cells treated with collagen I, leading to an underestimate of the extent of association of DDR1 with TM4SF1 (Figures S4B , S4E, and S4F). The results showed that soluble collagen I induces DDR1 aggregation at the cell surface (Figures 4D , top, and 4E) and concomitant recruitment of TM4SF1 ( Figure 4D , bottom). Silencing of TM4SF1 suppressed collagen-induced clustering of DDR1, indicating that TM4SF1 is required for this process (Figures 4E and S4H) . Similar results were obtained with a DDR1-blocking monoclonal antibody (Figure 4F) . Notably, this antibody, which binds to the discoidin-like domain of DDR1 and blocks its activation (Carafoli et al., 2012) , also inhibited the association of DDR1 with TM4SF1 and increased the solubility of DDR1 ( Figure S4G ). In contrast, function-blocking antibodies to the b1 integrin subunit, inhibition of ROCK with Y-27632, or inhibition of myosin II with blebbistatin did not interfere with collagen-induced clustering of DDR1, excluding participation of integrin-mediated signaling or myosin II contraction in this process (Figures 4F and S4I) . Comparison of the kinetics of cluster assembly and disassembly revealed that the clusters induced by soluble collagen I persisted for 3 hr or more at the cell surface, but those induced by collagen IV, which forms networks, were short-lived ( Figure S4J ). Taken together, these findings suggest that collagen I enhances the association of DDR1 with TM4SF1, enabling the formation of large and persistent DDR1-TM4SF1 clusters at the cell surface, whereas collagen IV induces short-lived clusters.
DDR1's Prometastatic Function Does Not Require Its Kinase Activity
In breast cancer cells exposed to collagen I, clustering of DDR1 declined before full activation of its kinase domain, suggesting that these two processes proceed independently (Figures 4G and S4J) . Consistently, silencing of TM4SF1, and hence disruption of DDR1 clustering, did not inhibit DDR1 kinase activation ( Figure 4G ). Conversely, inhibition of DDR1 kinase with ponatinib or imatinib (Bantscheff et al., 2007; Canning et al., 2014) blocked DDR1 autophosphorylation but did not interfere with DDR1 clustering ( Figures 4H and S4K ). These results suggest that DDR1 clustering and kinase domain activation can proceed independently and have distinct consequences.
Depletion of DDR1 inhibits non-small cell lung cancer metastasis to the bone (Valencia et al., 2012) . To examine the role of DDR1 in breast cancer metastasis, we silenced DDR1 or overexpressed a kinase-dead mutant. Strikingly, whereas depletion of DDR1, but not DDR2, inhibited the capacity of ErbB2 cells to form tumor spheres in vitro ( Figures S4L-S4O ), pharmacological or dominant-negative inhibition of DDR1 kinase did not interfere with this process (Figures S4P-S4S) . Similarly, silencing of DDR1, but not expression of kinase-dead DDR1, abrogated the capacity of ErbB2 cells to colonize the lung ( Figures 4I and  4J ). These results suggest that DDR1 promotes tumor sphere formation and lung colonization through a kinase-independent mechanism.
TM4SF1 Mediates Non-canonical DDR1 Signaling
The cytoplasmic C-terminal Cys residue of TM4SF1 binds to one of the two N-terminal PDZ domains of syntenin 2 (Borrell-Pagè s et al., 2000). While little is known about syntenin 2, its homolog syntenin 1 has been implicated in the activation of protein kinase (legend continued on next page) C (PKC), focal adhesion kinase (FAK), and nuclear factor kappalight-chain-enhancer of activated B cells (NF-kB) (Sarkar et al., 2008) . Mutation of the C-terminal cysteine of TM4SF1 (C202G) disrupted its interaction with syntenin 2 ( Figure S5A ) and its capacity to promote lung colonization by 4TO7 cells ( Figure 5A ). Conversely, silencing of syntenin 2 suppressed lung colonization by the TM4SF1-proficient ErbB2 cells ( Figure 5B ). Ectopic expression experiments indicated that syntenin 2 combines with DDR1 only in the presence of TM4SF1 ( Figures S5B and  S5C ). Moreover, silencing of TM4SF1 inhibited the interaction of endogenous DDR1 with syntenin 2 in ErbB2 cells ( Figure S5D ), suggesting that TM4SF1 functions as a membrane adaptor linking DDR1 to syntenin 2. To gain insight into the signaling pathways activated by TM4SF1 via syntenin 2, we performed overexpression experiments. Wild-type TM4SF1 and syntenin 2, but not TM4SF1-C202G, promoted activation of conventional and novel PKC isoforms and phosphorylation of STAT3 in 4TO7 cells; they did not, however, affect the activation of FAK, NF-kB, and p38 kinase ( Figures S5E and S5F) . Subsequent experiments showed that soluble collagen I induces two waves of signaling in ErbB2 cells. Conventional PKC isoforms and JAK2 were activated in a biphasic fashion with peaks at 30 min and 6 hr following exposure to soluble collagen I. In contrast, DDR1 and STAT3 became phosphorylated at around 3 hr and persisted in an activated form up to at least 12 hr ( Figure S5G ). Silencing of TM4SF1 suppressed collagen-induced phosphorylation of PKCa, activation of total PKC, and phosphorylation and activation of JAK2 and STAT3, indicating that DDR1 activates PKCa and JAK2/STAT3 signaling through TM4SF1 ( Figures 5C, 5D , and S5H). Inhibition of JAK2 with fedratinib or AZD1480 did not affect collagen I-induced activation of total PKC, suggesting that JAK2 does not function upstream of PKC ( Figure 5E ). In contrast, inhibition of conventional and novel PKC isoforms with Gö 6976 or GF109203X (Bis I) (Wu-Zhang and Newton, 2013) inhibited this process, confirming the involvement of these isoforms in the response to collagen I ( Figure 5E ). Notably, Gö 6976 and Bis I blocked collagen-induced activation of JAK2 and STAT3, placing PKC upstream of JAK/STAT signaling. Consistently, pharmacological inhibition of JAK2 with fedratinib or AZD1480 suppressed activation of STAT3 but not PKC ( Figure 5F ). Finally, inhibition of DDR1 kinase activity with imatinib did not affect activation of PKC, JAK2, and STAT3 in response to collagen I (Figures 5E and 5F ). These results suggest that TM4SF1 mediates non-canonical DDR1 signaling by promoting activation of PKC and hence of JAK2 and STAT3.
To confirm the involvement of PKC in activation of JAK2-STAT3 signaling, we examined the effect of phorbol 12-myristate 13-acetate (PMA), which functions as an allosteric activator of conventional PKC. Treatment with PMA caused rapid and robust activation of JAK2 and subsequent activation of STAT3 in ErbB2 cells, demonstrating that conventional PKC can activate JAK2-STAT3 signaling ( Figure 5G ). In agreement with the hypothesis that TM4SF1 recruits PKCa through syntenin 2, PKCa combined efficiently with syntenin 2, but not TM4SF1, in 293T cells ( Figures  S5I and S5J ). In contrast, JAK2 interacted with DDR1 and PKCa, but not with TM4SF1 or syntenin 2 ( Figure S5K ). These results suggest that DDR1, TM4SF1 and syntenin 2 cooperate to recruit and activate PKCa and JAK2.
We next considered the potential role of PKCa in the activation of JAK2. In vitro kinase assays indicated that recombinant PKCa promotes phosphorylation of JAK2 ( Figures 5H and S5L) . Mass spectrometric analysis revealed that PKCa phosphorylates JAK2 at two evolutionarily conserved residues: T174 in the N-terminal FERM domain and S518 in the segment that adjoins the SH2-like domain to the pseudo-kinase domain (Figures S5M  and S5N ; Table S4 ). Mutation of either residue to alanine inhibited the ability of JAK2 to phosphorylate GST-STAT3, suggesting that both sites regulate kinase activity ( Figure 5I ). Based on existing structural data, we presume that phosphorylation of T174 and S518 contributes to disrupt negative regulatory interactions that the FERM domain and the SH2-like-pseudokinase domain of JAK2 establish with DDR1 or the pseudokinase-kinase domains of JAK2 (Brooks et al., 2014; Shan et al., 2014; Toms et al., 2013) . These results suggest that PKC activates JAK2 and thereby STAT3 by directly phosphorylating T174 and S518. Collectively, these studies indicate that TM4SF1 promotes non-canonical DDR1 signaling by recruiting syntenin 2 and PKC, thus allowing transphosphorylation and activation of JAK2 ( Figure 5J ).
(C) 293FT cells were co-transfected with Myc-TM4SF1 together with Flag-DDR1, Flag-TrkA-DDR1 (extracellular domain chimera), Flag-DDR1 609* (intracellular domain truncation), Flag-DDR1 529* (intracellular domain truncation), or empty vector and were coIP with anti-Flag. Flag coIP and total lysates were subjected to IB with the indicated antibodies. (D) ErbB2 cells were treated with or without 10 mg/ml coll I for 30 min, stained with anti-DDR1 and counterstained with the plasma membrane dye FM-4 64 (PM) and DAPI. Representative images (top panels). Myc-TM4SF1 and HA-DDR1 co-transfected 293FT cells were treated with or without 10 mg/ml collagen I for 30 min and stained with anti-HA and anti-TM4SF1 followed by counterstaining with DAPI. Representative images of co-transfected cells (bottom panels). (E) ErbB2 cells were treated with or without 10 mg/ml collagen I for 30 min and stained with anti-DDR1 antibody and DAPI. Representative images (top) and surface fluorescence intensity plots (bottom). The insets show high magnification images of a portion of the plasma membrane adjacent to the boundary of the nucleus demarcated by white dotted lines (bottom). (F) Control and TM4SF1-silenced MDA-MB231 cells were treated with or without 10 mg/ml collagen I for 30 min. When indicated, cells were pretreated with 10 mg/ml anti-DDR1 or anti-iTGB1 (integrin b1) function-blocking monoclonal antibodies. Number of DDR1 clusters per microscopic field. Mean values (±SD); p values; Student's t test. (G) ErbB2 cells transfected with control or TM4SF1-specific small interfering RNA (siRNA) SMARTpools were treated with 10 mg/ml coll I for the indicated times, and coIP with anti-DDR1. Immunoprecipitates were subjected to IB with the indicated antibodies. (H) ErbB2 cells were treated with or without 10 mg/ml collagen I for 30 min, alone or in combination with 100 nM ponatinib or imatinib, and then subjected to staining with anti-DDR1 followed by DAPI. Number of DDR1 clusters per microscopic field (±SD). p values; Student's t test. (I and J) Control (sh-co) or DDR1-silenced (sh 6 and sh 7) (I) and control (vector) or DDR1-P529*-overexpressing (J) ErbB2-TGL cells were inoculated i.v. in nude mice. Lung metastasis was measured by BLI. Normalized photon flux at the indicated times (left (±SD) and representative images (right); p values; Student's t test. See also Figure S4 . Non-canonical DDR1 Signaling Sustains CollagenDependent Outgrowth and Metastasis Inactivation of PKC, JAK2, or STAT3 suppressed collagen I-induced tumor sphere formation but not DDR1 clustering, implicating non-canonical DDR1 signaling in collagen I-induced self-renewal ( Figures 6A, S6A , and S6B). In agreement with the identification of SOX2 as a STAT3 target gene (Chen et al., 2008) , transient silencing of TM4SF1 or inhibition of PKC, JAK2, or STAT3 suppressed the expression of Sox2 but not Oct4 or Nanog (Figures 6B and 6C) . Presumably, prolonged inhibition of non-canonical DDR1 signaling via stable depletion of TM4SF1 had downregulated all three pluripotency factors (Figure 2E ) because they are connected by self-sustaining interactions (Young, 2011) . Notably, transient depletion of Sox2 or Nanog but not Oct4 suppressed tumor sphere formation, suggesting that these two factors control breast cancer self-renewal in vitro ( Figures 6D and 6E) .
To dissect the role of the PKCa-STAT3 pathway in metastasis, we tested the effect of kinase-dead forms of PKCa, PKCb II, PKCd, and PKCz on lung colonization. Consistent with a specific involvement of PKCa (Tam et al., 2013) , only expression of dominant-negative PKCa blocked lung colonization ( Figures 6F,  6G , and S6C). Silencing of STAT3 exerted a similar inhibitory effect ( Figures 6H, 6I , and S6D-S6G). These findings implicate PKCa-STAT3 signaling in metastatic outgrowth.
To corroborate the involvement of non-canonical DDR1 signaling in cancer stem cell self-renewal and metastatic reactivation, we first verified that silencing of DDR1 or syntenin 2 suppresses the capacity of ErbB2 cells to form tumor organoids in 3D Matrigel ( Figure S6H ). We then examined lung sections from mice that had been inoculated with DDR1-, syntenin 2-, or STAT3-silenced ErbB2 cells and relative controls. The results indicated that silencing of DDR1, syntenin 2, or STAT3 selectively blocks the ability of solitary tumor cells to exit from dormancy and outgrow into metastatic lesions ( Figure S6I ). Finally, we investigated the effect of silencing of DDR1 or syntenin 2 on reactivation in other target organs. Depletion of each component suppressed the capacity of ErbB2 cells to colonize the bone and brain ( Figures 6J, S6J , and S6K) by preventing solitary tumor cells from resuming proliferation in these organs ( Figure S6L ). Together, these results implicate several essential elements of non-canonical DDR1 signaling in reactivation from dormancy at multiple metastatic sites.
TM4SF1 Couples DDR1 to Activation of STAT3 during Tumor Progression
To study non-canonical DDR1 signaling during tumor progression and metastasis, we evaluated the deposition of collagen I in the mammary carcinomas and metastatic outgrowths of MMTV-Neu(YD) mice, which provide a faithful model of metastatic HER2 + breast cancer (Guo et al., 2006) . The pre-neoplastic lesions and mammary intraepithelial neoplasia (MIN) lesions, which were identified by their expression of Neu and the presence of a large percentage of Ki-67-positive cells, were separated from the surrounding interstitial matrix by an intact basal lamina ( Figure 7A ). Although advanced MIN lesions had a partially disrupted basal lamina and were surrounded by collagen fibers, Masson Trichrome and Picrosirius staining revealed large thick bundles of collagen surrounding tumor cell nests only in advanced adenocarcinomas (Figures 7A and S7A) . These findings indicate that breast cancer cells come in contact with collagen I after they disrupt the underlying basement membrane and invade into the interstitium. Staining of lung sections from 5-month-old mice with anti-Neu revealed several micrometastic lesions, often associated with bronchioles or blood vessels. The micrometastases, and the larger metastases that they generated, did not deposit basement membrane components, such as collagen IV, but were surrounded by collagen I fibrils ( Figure S7B ). These fibrils appeared orange under orthogonal polarized light after Picrosirius staining. However, they were not stained in blue by the Masson Trichrome method, pointing to an intermediate level of macromolecular organization ( Figure S7B ). These results suggest that the tumor cells within incipient metastatic lesions or the stromal cells that they recruit can assemble a collagen I-rich metastatic niche. To capture an earlier stage of metastatic outgrowth, we inoculated mice intravenously with ErbB2 cells and subjected lung sections to staining with antibodies to Neu, collagen I, and Ki-67. We found that the majority of solitary tumor cells in contact with collagen I and those within micrometastatic lesions had resumed proliferation, whereas the majority of solitary tumor cells not in contact with collagen I were quiescent ( Figures 7B and S7D ). These (B) Control (sh-co) or syntenin 2-silenced (sh 1 and sh 3) ErbB2-TGL cells were subjected to IB as indicated (left top), and inoculated i.v. in nude mice. Lung metastasis was measured by BLI. Normalized photon flux at the indicated times (left bottom) and representative images (right). Error bars, mean ± SD p values Student's t test. (C) Control or TM4SF1-specific siRNA (SMART pool) transfected ErbB2 cells were treated with 50 mg/ml collagen I for the indicated times. Total lysates were subjected to IB with the indicated antibodies. (D-F) ErbB2 cells transfected with control or TM4SF1-specific siRNA SMARTpools were treated with coll I, alone or in combination with GÖ 6976 (50 nM), bisindolylmaleimide I (Bis I, 300 nM), fedratinib (1 mM), AZD1480 (100 nM), or imatinib (100 nM), lysed, and subjected to a PKC kinase assay (D and E) 
or immunoblotting (F). Mean values (±SD); p values Student's t test (D and E).
(G) ErbB2 cells were treated with 100 nM PMA for the indicated times and subjected to IB. (H) Purified recombinant PKCa and JAK2 were admixed in vitro, alone or in combination with PMA (PKC activator, 50 nM) or GÖ 6976 (PKC inhibitor, 100 nM), as indicated, and subjected to in vitro kinase assay with radioactive ATP. (I) JAK2-deficient g2A cells were transfected with wild-type (WT) or mutant forms of Flag-JAK2. Total lysates were subjected to in vitro kinase assay with cold ATP and GST-STAT3 as substrates. Samples were subjected to IB as indicated. Note these cells possess elevated levels of endogenous phosphorylated PKC. Wildtype JAK2, but none of phosphorylation site mutants, induces phosphorylation of GST-STAT3 at Y705. An endogenous activity induces phosphorylation of STAT3 at S727, serving as an internal control. (J) Model of non-canonical DDR1 signaling. Kinase-dependent pathways are shaded gray. See also Figure S5 . Figure 6 . Non-canonical DDR1 Signaling Promotes Self-Renewal In Vitro and Lung Metastasis In Vivo (A) ErbB2 cells were treated with 50 mg/ml coll I alone or combination with GÖ 6976 (50 nM), Bis I (300 nM), fedratinib (1 mM), Stattic (2.5 mM), BP-1-102 (20 mM), and ponatinib (100 nM) or they were transduced with DDR1 shRNAs (6 and 7) before treatment with coll I. The graph shows the number of tumor spheres formed per 10 3 cells seeded (±SE). P values, unpaired Student's t test.
(B) ErbB2 cells transfected with control or TM4SF1-specific siRNA SMARTpools were subjected to qPCR analysis (±SE).
(C) ErbB2 cells were treated with DMSO or GÖ 6976 (50 nM) (top), fedratinib (1 mM) (middle), and Stattic (2.5 mM) (bottom), and subjected to qPCR analysis (±SE).
(legend continued on next page) findings are consonant with the hypothesis that contact with collagen I is required for or triggers metastatic reactivation. Examination of the expression of DDR1 and TM4SF1 revealed that both are upregulated at the transition from advanced MIN lesion to invasive adenocarcinoma in MMTV-Neu(YD) mice (Figure S7C) . However, whereas the primary tumors of these mice contained a small percentage of P-STAT3-positive cells, the lung metastases had a large number of tumor cells exhibiting strong nuclear staining for P-STAT3 ( Figure S7C ). This suggests that non-canonical DDR1 signaling to STAT3 is activated during tumor progression and initial metastatic outgrowth.
Finally, we studied the expression of DDR1, TM4SF1, and P-STAT3 in TMAs containing primary cancers and metastatic lesions. Whereas primary tumors and metastases exhibited similar levels of DDR1 and TM4SF1, P-STAT3 was significantly upregulated in metastases ( Figure 7C ). Analysis of matched samples confirmed this finding ( Figure 7D ). Consistent with the specific upregulation of STAT3 in metastases, the levels of P-STAT3 staining of primary tumors did not correlate positively with early relapse, but those of metastatic lesions retrospectively correlated with reduced time to progression ( Figures 7E and S7E ). These findings corroborate the importance of P-STAT3 signaling in human breast cancer metastasis.
DISCUSSION
We have identified a novel signaling mechanism that enables breast cancer cells to exploit the most abundant component of the extracellular matrix, fibrillar collagen, to undergo metastatic reactivation in multiple organs. The tetraspanin TM4SF1 functions in this process by coupling DDR1 to syntenin 2 and hence PKCa. The latter activates JAK2 and its transcriptional effector STAT3, thus impinging on pluripotency factors, which sustain the self-renewal capacity of metastasis-initiating cells. Experiments involving inducible expression of TM4SF1 in dormant cells or inactivation of TM4SF1 and other key components in metastatic cells corroborate the role of non-canonical DDR1 signaling in metastatic reactivation.
Extensive evidence suggests that highly cross-linked collagen fibers promote tumor progression and metastasis by activating an integrin mechanotransduction pathway involving Rho-mediated contraction of the actin cytoskeleton and enhanced FAK/ Src signaling (Erler et al., 2006; Levental et al., 2009; Paszek et al., 2005; Samuel et al., 2011) . In contraposition, our results indicate that soluble fibrillar collagen I, and presumably other fibrillar collagens, enhance the manifestation of cancer stem cell traits, such as the expression of pluripotency transcription factors, the formation of tumor spheres, and the ability to initiate tumor outgrowth, by activating non-canonical DDR1 signaling independently of integrin engagement. Additional genetic experiments implicate this novel signaling pathway in metastatic reactivation, thus reinforcing the connection between the most basic cellular attribute of cancer stem cells-the capacity for selfrenewal-and metastatic reactivation.
We speculate that DDR1 signaling and integrin mechanotransduction may not only proceed independently, as suggested previously (Vogel et al., 2000) and in this paper, but also have opposing functions in certain contexts. For example, inhibition of integrin-mediated mechanotransduction with the Rho-kinase inhibitor Y27632 promotes the outgrowth and propagation of normal and tumor organoids in 3D Matrigel (Gao and Chen, 2015) . Conversely, DDR1 inhibits integrin a2b1 signaling in MDCK cells migrating in collagen gels (Wang et al., 2006) . These considerations suggest that integrin mechanotransduction and non-canonical DDR1 signaling regulate distinct steps of the invasion-metastasis cascade: the former predominantly mediating survival and invasive growth through dense extracellular matrices in advanced primary tumors, and the latter enabling cancer stem cell self-renewal and metastatic reactivation in the interstitial matrix of target organs.
Non-canonical DDR1 signaling possesses several distinguishing features, including its dependence on the nucleation of large membrane signalosomes and its complex kinetics (see the Supplemental Discussion). Although we cannot exclude the involvement of additional transcriptional effectors, our results have revealed that engagement of DDR1 by collagen I controls self-renewal and metastatic reactivation through activation of STAT3, which prior studies had considered to be only responsive to stroma-derived IL6 (Yu et al., 2014) . Consistent with the identification of SOX2 as a direct target of STAT3 (Chen et al., 2008; Zhao et al., 2014) , acute inactivation of TM4SF1 or STAT3 suppressed the expression of SOX2, but not NANOG or OCT4, and tumor sphere formation, suggesting that non-canonical DDR1 signaling to SOX2 is required for self-renewal in vitro. Acute depletion of NANOG, but not OCT4, also inhibited tumor sphere formation, implicating both SOX2 and NANOG in this process. Since stable depletion of TM4SF1 led to downregulation of all three pluripotency factors presumably because of their participation in a self-sustaining transcriptional network (Young, 2011) , we hypothesize that non-canonical DDR1 signaling controls breast cancer stem cell behavior by inducing SOX2 directly and NANOG indirectly. In support of the clinical relevance of non-canonical DDR1 signaling, a discrete 8-gene signature controlled by TM4SF1 exhibited a strong ability to predict metastatic relapse across breast cancer subtypes. In addition, immunohistochemical analysis of matched primary and metastatic samples revealed that the cancer cells within metastases contain significantly higher levels of nuclear P-STAT3 as compared to those in primary tumors. Among the metastases, the highest levels of P-STAT3 were present in those that had occurred after a short disease-free interval. Because neither TM4SF1 nor DDR1 levels increased in the metastases of MMTV-Neu mice and breast cancer patients, it is possible that additional pathway components are upregulated during tumor progression leading to positive selection of tumor cells in which non-canonical DDR1 signaling can be fully activated on contact with collagen I in the stroma of target organs. We presume that this selection occurs within primary cancers because expression of the TM4SF1 signature in primary tumors predicts metastatic relapse.
It has been proposed that inhibition of niche signals may significantly enhance the efficacy of chemotherapy and oncogene-targeted therapy in metastatic disease (Ghajar, 2015; Giancotti, 2013) . Non-canonical DDR1 signaling emerges from our study as a general niche signal and a prime target for this novel therapeutic approach. Based on our findings, we propose that antibodies and other biological disrupting the association of DDR1 with TM4SF1 or novel and safe JAK2 kinase inhibitors may display efficacy in the adjuvant setting or, in combination with chemotherapy or oncogene-targeted therapy, in the treatment of metastatic breast cancer.
EXPERIMENTAL PROCEDURES Animal Studies
All mouse studies were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee of Memorial Sloan Kettering Cancer Center (MSKCC). Details are provided in the Supplemental Experimental Procedures.
Doxycycline-inducible Metastatic Reactivation
4TO7-TGL cells were infected with pCW-Myc-TM4SF1 and inoculated intravenously into syngeneic mice. Doxycycline was administered to mice through the diet (625 mg/kg of food) as well as by intraperitoneal injection (25 mg/kg of body weight; three times a week). Doxycycline was administrated either immediately after injection of the cancer cells or 14 days later. Bioluminescent imaging was used to verify successful injection and to monitor metastatic outgrowth. Metastatic lesions were confirmed by histological analysis.
Tumor Sphere Assays
Mammosphere assays were performed as previously described (Dontu et al., 2003) . Single cells suspension of ErbB2 and MDA-MB231 cells (1,000 cells/ml) were plated on ultra-low attachment plates and cultured in serum-free MEBM supplemented with 5 mg/ml insulin, 0.5 mg/ml hydrocortisone, 1:50 B27, 20 ng/ml basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF), and 4 mg/ml insulin and heparin for 10 days. When indicated, purified collagen I was added at 50 mg/ml. Tumor spheres were visualized under phase contrast microscope, photographed, and counted. For serial passage, tumor spheres were collected using 70-mm cell strainers and dissociated with Accutase for 30 min at 37
C to obtain single-cell suspensions.
DDR1 Clustering
293FT transfected with HA-DDR1 and Myc-TM4SF1 or control and TM4SF1-silenced ErbB2 cells were deprived of growth factors for 12 hr and then treated with soluble collagen I or IV for the indicated times followed by fixation with 4% PFA for 10 min at 4 C. When indicated, inhibitory mouse monoclonal DDR1 antibodies were added at the indicated concentrations prior to exposure to collagen I. Fixed cells were washed with PBS, permeabilized with 0.2% Triton X-100 for 20 min, stained with a rabbit monoclonal antibody cross reactive with both mouse and human DDR1 (clone D1G6), alone or in combination with phalloidin, FM4-64 membrane dye (Molecular Probes), mouse monoclonal anti-HA antibody (Clone16B12), or rabbit anti-TM4SF1 antibody, and counterstained with DAPI. The data were quantified by ImageJ 1.48b and represented graphically.
Human Pathology
Paraffin-embedded tissue microarray sections with multiple cores of primary breast tumors or lung metastatic lesions were obtained from the MSKCC Department of Pathology in compliance with protocols approved by the MSKCC Institutional Review Board and after the subjects gave their informed consent. The levels of expression of TM4SF1 and DDR1 and of activation of STAT3 were determined by immunohistochemical staining. TM4SF1, DDR1, or P-STAT3 immunoreactivity was evaluated and scored by a clinical pathologist (E.B.). Metastasis-free survival was analyzed as a function of TM4SF1 or P-STAT3 abundance in breast tumor samples or lung metastatic samples.
DNA Microarray Analysis
Standard methodology was used to extract, label, and hybridize the cDNAs to the MouseRef8 gene expression chip (Illumina). Data were analyzed in Partek.
Statistical Analysis
Results are reported as mean ± SD or mean ± SEM unless otherwise noted. Comparisons between two groups were performed using an unpaired twosided Student's t test (p < 0.05 was considered significant).
ACCESSION NUMBERS
The accession number for the gene expression data of 4TO7 and 4TO7-TM4SF1 reported in this paper is Gene Expression Omnibus: GSE62730. See also Figure S7 .
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